Cortexyme announces publication of foundational data for groundbreaking approach to treating Alzheimer's disease in Science Advances
Researchers identify Porphyromonas gingivalis as a key driver of Alzheimer's disease pathology and demonstrate potential for small molecule inhibitors to block the pathogen. The discovery paves the way for Cortexyme's lead compound COR388, which shows promising results in preclinical experiments.